These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 21794577)

  • 1. [A study on the subjective compliance and acceptance of oral lanzoprazole in traumatology. The ECOFT-TR Study].
    Márquez-Contreras E; Gil-Guillén V; Nadal-Sánchez A; Plazas-Fernández MJ; Heras-Navarro J; Galván-Cervera J; Porcel-Carbonell J
    Reumatol Clin; 2009; 5(2):49-54. PubMed ID: 21794577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological compliance and acceptability of lansoprazole orally disintegrating tablets in primary care.
    Márquez-Contreras E; Gil V; López J; Plazas MJ; Heras J; Galván J; Porcel J
    Curr Med Res Opin; 2008 Feb; 24(2):569-76. PubMed ID: 18194594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acceptability of lansoprazole orally disintegrating tablets in patients with gastro-oesophageal reflux disease : ACEPTO study.
    de Argila CM; Ponce J; Márquez E; Plazas MJ; Galván J; Heras J; Porcel J
    Clin Drug Investig; 2007; 27(11):765-70. PubMed ID: 17914895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation of preferences in patients with gastroesophageal reflux disease and dysphagia concerning treatment with lansoprazole orally disintegrating tablets].
    Blanco MA; Prieto M; Mearin F; Plazas MJ; Armengol S; Heras J; Mas M; Piqué JM;
    Gastroenterol Hepatol; 2009 Oct; 32(8):542-8. PubMed ID: 19595483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease.
    Nausieda PA; Pfeiffer RF; Tagliati M; Kastenholz KV; DeRoche C; Slevin JT
    Clin Ther; 2005 Jan; 27(1):58-63. PubMed ID: 15763606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Open-label study of mirtazapine orally disintegrating tablets in depressed patients in the nursing home.
    Roose SP; Nelson JC; Salzman C; Hollander SB; Rodrigues H;
    Curr Med Res Opin; 2003; 19(8):737-46. PubMed ID: 14687445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapidly disintegrating risperidone in subjects with schizophrenia or schizoaffective disorder: a summary of ten phase I clinical trials assessing taste, tablet disintegration time, bioequivalence, and tolerability.
    Thyssen A; Remmerie B; D'Hoore P; Kushner S; Mannaert E
    Clin Ther; 2007 Feb; 29(2):290-304. PubMed ID: 17472821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
    Adachi JD; Hanley DA; Lorraine JK; Yu M
    Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acceptability and tolerability of levetiracetam oral solution for the treatment of partial-onset seizures: the SOLUCIÓN study.
    Matías-Guíu J; Molins A; Mauri JA; Villar E
    Methods Find Exp Clin Pharmacol; 2010 Sep; 32(7):507-16. PubMed ID: 21069102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter, randomized, double-blind, active-controlled, parallel-group trial of the long-term (6-12 months) safety of acetaminophen in adult patients with osteoarthritis.
    Temple AR; Benson GD; Zinsenheim JR; Schweinle JE
    Clin Ther; 2006 Feb; 28(2):222-35. PubMed ID: 16678643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tacalcitol in the treatment of psoriasis vulgaris: the Spanish experience.
    Lecha M; Mirada A; López S; Artés M;
    J Eur Acad Dermatol Venereol; 2005 Jul; 19(4):414-7. PubMed ID: 15987284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years.
    Grossman LD; Parlan G; Bailey AL; Yee G; Yu M; Chan JY
    Clin Ther; 2009 Jan; 31(1):74-88. PubMed ID: 19243708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
    Simpson DM; Messina J; Xie F; Hale M
    Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
    Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
    Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Analysis of therapeutic compliance in women with osteoporosis].
    Carbonell Abella C; Guañabens Gay N; Regadera Anechina L; Marín Rives JA; Taverna Llauradó E; Ayechu Redín MP;
    Reumatol Clin; 2011; 7(5):299-304. PubMed ID: 21925445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets.
    Sheftell FD; Dahlöf CG; Brandes JL; Agosti R; Jones MW; Barrett PS
    Clin Ther; 2005 Apr; 27(4):407-17. PubMed ID: 15922814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knowledge and compliance from patients with postmenopausal osteoporosis treatment.
    Palacios S; Sánchez-Borrego R; Neyro JL; Quereda F; Vázquez F; Pérez M; Pérez M
    Menopause Int; 2009 Sep; 15(3):113-9. PubMed ID: 19723681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ease of use and preference for a new disposable self-injection pen compared with a reusable pen for administering recombinant human growth hormone: A multicenter, 2-month, single-arm, open-label clinical trial in patient-caregiver dyads.
    Hey-Hadavi J; Pleil A; Deeb LC; Fuqua JS; Silverman LA; Reiner B; Newfield R; Rajicic N; Wajnrajch MP; Cara JF
    Clin Ther; 2010 Nov; 32(12):2036-47. PubMed ID: 21118739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Raloxifene in clinical practice. Results of the non-interventional study CORAL (COmpliance with RALoxifene)].
    Rosa J; Vanuga P; Payer J; Svobodník A
    Vnitr Lek; 2008 Mar; 54(3):217-9, 221-4. PubMed ID: 18522288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
    Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
    Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.